Research Highlights
Biomerica, Inc. (Nasdaq: BMRA), a global biomedical technology company focused on innovative diagnostic-guided therapies, today announced that an abstract evaluating the real-world clinical effectiveness of its inFoods® IBS diagnostic-guided therapy has been accepted for poster presentation at Digestive Disease Week® (DDW) 2026. DDW is the world’s largest gathering of physicians, researchers, and industry professionals in gastroenterology, hepatology, and related GI disciplines. Acceptance of this poster reflects the growing interest within the gastroenterology community in personalized, non-pharmacologic dietary management strategies for patients with irritable bowel syndrome (IBS).
Key Data and Findings
- Title: Novel IBS-specific Guided Elimination Diet Significantly Reduces Abdominal Symptoms in Individuals With IBS: A Real-world Experience
- Authors: Bill Hirsch, MD (University of Michigan), William D. Chey, MD (University of Michigan), Anthony Lembo, MD (Cleveland Clinic), Prashant Singh, MD (University of Michigan)
- Display Time: May 2, 2026 at 12:30 to 1:30 pm CT, McCormick Place, Chicago, IL
The real-world study will be presented by investigators from Michigan Medicine (University of Michigan) and Cleveland Clinic. The study builds on findings from a multicenter, double-blinded, placebo-controlled trial of the inFoods® IBS test published in the June 2025 issue of Gastroenterology. Per DDW embargo policy, study data will be made available beginning at 12:01 a.m. CDT on the day of presentation.
About inFoods® IBS
inFoods® IBS is a diagnostic-guided therapy that identifies patient-specific food triggers responsible for symptoms such as abdominal pain, bloating, diarrhea, and constipation. Using a simple finger-stick blood sample, the test enables physicians to recommend targeted dietary changes tailored to the patient’s immune response—offering a non-pharmaceutical, precision-based approach to symptom relief.
A multicenter, double-blinded sham-controlled trial on the inFoods® IBS test was published in the June 2025 issue of Gastroenterology, a peer-reviewed GI journal. The study demonstrated statistically significant outcomes:
- 59.6% of patients in the treatment group (who eliminated identified trigger foods) achieved the FDA’s endpoint for abdominal pain reduction, compared to 42.1% in the control group.
- Among IBS-C patients, 67.1% of patients in the treatment group vs. 35.8% in the control group.
- Among IBS-M patients, 66% of patients in the treatment group vs. 29.5% in the control group.
About Irritable Bowel Syndrome (IBS)
IBS affects an estimated 30 to 45 million adults in the United States, representing 10%–15% of the adult population. The condition leads to decreased quality of life, lost productivity, and reliance on medications with adverse side effects. Current IBS drugs address symptoms without targeting the underlying dietary triggers specific to each patient.
inFoods® IBS takes a fundamentally different approach—a precision diagnostic that identifies individual food triggers via a simple finger-stick blood test, enabling targeted, patient-specific dietary recommendations. This non-pharmacologic, personalized solution addresses a significant unmet clinical need within an estimated $30 billion total addressable market.
About Biomerica
Biomerica, Inc. is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company’s primary focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in commercialization.